News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Artiva Biotherapeutics (NASDAQ:ARTV) reported a quarterly loss of $0.63 per share, beating analyst estimates. The stock, currently trading around $11.58, has seen significant insider buying totaling nearly $107.7 million over the past 90 days. Analysts maintain a "Moderate Buy" consensus with a target price …
Artiva Biotherapeutics Inc. reported quarterly earnings per share (EPS) of $-0.63. This financial update, originally sourced from Reuters, provides key information for investors and market watchers interested in the company's recent performance. The article focuses solely on this financial figure without further elaborating on …
Artiva Biotherapeutics reported a net loss of $25.0 million for Q2 2026 and holds $349.4 million in cash, cash equivalents, and investments, projected to fund operations into 2029. The company highlighted clinical progress for its AlloNK program, including FDA's RMAT designation for AlloNK plus …
Artiva Biotherapeutics reported its Q2 2026 financial results, highlighting significant progress with its lead program, AlloNK. The company announced positive clinical data for AlloNK in treating refractory rheumatoid arthritis (RA) and other autoimmune diseases, received FDA RMAT designation for AlloNK in refractory RA, and …
Artiva Biotherapeutics (ARTV) has demonstrated strong clinical progress for its AlloNK therapy in autoimmune diseases, showing 71% ACR50 response in refractory RA patients with good safety. The FDA's RMAT designation and a recent $300 million capital raise are supporting the launch of a Phase …
Certain stock options of Artiva Biotherapeutics, Inc. will be under a 91-day lock-up period, starting from May 8, 2026, and ending on August 7, 2026. During this period, officers, directors, and affiliated funds are restricted from selling, offering, or otherwise disposing of these stock …
This article provides a comprehensive overview of Artiva Biotherapeutics, Inc. (ARTV) stock, including its current price, historical performance, and key financial data. It highlights the company's focus on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers, detailing its lead product candidates …
This article from Investing.com reports on a Form DEF 14A filing by Artiva Biotherapeutics, dated for August 3rd. It includes the stock symbol ARTV and notes a -0.09% change for the company. The content primarily focuses on this regulatory filing and is embedded within …
RA Capital Management, a 10% owner and director of Artiva Biotherapeutics (NASDAQ:ARTV), recently acquired common stock totaling $455,725 through multiple transactions in late July 2026. This investment comes as Artiva's shares have surged 257% over the past year, with analysts maintaining a strong buy …
Analysts have issued a "Moderate Buy" rating for Artiva Biotherapeutics (NASDAQ:ARTV), with an average 12-month price target of $39.00, significantly higher than its current share price of $10.11. The company recently reported a quarterly loss, missing analyst estimates, but insiders have been substantial net …
This article provides a valuation analysis for Artiva Biotherapeutics Inc (ARTV), noting its current valuation score is 8.85, ranking 46 out of 385 in its industry. The company's P/E ratio is -2.85, significantly below its recent high but above its recent low. Key valuation …
Artiva Biotherapeutics Inc (ARTV) has a weak financial status, ranking 363 out of 385 in the Biotechnology & Medical Research industry with a financial score of 5.40. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow …
Artiva Biotherapeutics Inc (ARTV) has an institutional shareholding score of 5.00, placing it 132nd out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 68.82%, a decrease of 16.15% quarter-over-quarter. James Simons is the largest institutional shareholder, holding …
This article from Investing.com announces the filing of a Form 4 by Artiva Biotherapeutics Inc. for July 28. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders whenever they trade their company's securities. …
This article provides a basic overview of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) financial information available on TradingView. It appears to be a stub or an incomplete page, as it promises a "Revenue Breakdown" but only presents navigation and general information about TradingView's offerings without …
This article provides a comprehensive overview of Artiva Biotherapeutics Inc (ARTV) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial data spanning several fiscal years, allowing for an evaluation of the company's financial soundness and stability. The report …
This article provides historical dividend and stock split information for Artiva Biotherapeutics Inc (ARTV). It indicates that the company has distributed a total of 0.00 USD in dividends over the past five years and that there is no data available for past dividend dates. …
Artiva Biotherapeutics has announced the deadline for its 2026 annual meeting of stockholders, setting August 1, 2026, for submissions of business or director nominations. This timing, more than 70 days after the one-year anniversary of its 2025 meeting, necessitates this specific deadline for stockholder …
This article provides a detailed quarterly and annual income statement for Artiva Biotherapeutics Inc. (ARTV). It covers various financial metrics such as total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page also includes FAQs explaining how to …
This article reports on significant insider stock purchases that occurred on July 24, 2026, highlighting transactions involving ARTIVA BIOTHERAPEUTICS, INC. ($ARTV), PINNACLE FINANCIAL PARTNERS, INC. ($PNFP), CYTOMED THERAPEUTICS LTD ($GDTC), and BEAMR IMAGING LTD. ($BMR). It details the number of shares bought and estimated …
RA Capital Management, acting as a director and 10% owner of Artiva Biotherapeutics, recently purchased 264,586 common shares in open-market transactions. These purchases, made at weighted average prices between USD 9.55 and USD 9.96, increased their beneficial ownership to 17,242,483 common shares. This transaction …
RA Capital Management, a significant shareholder and director of Artiva Biotherapeutics (NASDAQ:ARTV), recently acquired approximately $2.58 million worth of additional shares in the company. These purchases, made over three days, increased their indirect beneficial ownership to over 17 million shares. The stock has seen …
This article from TradingView provides an overview of options volatility for Artiva Biotherapeutics, Inc. (ARTV) on NASDAQ. It highlights tools like implied volatility curves and ATM IV term structure to help traders assess market expectations and identify potential trading opportunities for crafting options strategies.
Artiva Biotherapeutics has scheduled its 2026 annual meeting for September 8, 2026. The company has set an August 1, 2026, deadline for stockholders to submit notices for director nominations or other business, and for Rule 14a-8 proxy proposals to be included in company materials. …
Artiva Biotherapeutics (Nasdaq: ARTV) has announced that its 2026 annual meeting of stockholders is scheduled for September 8, 2026. Due to this date being more than 70 days after the one-year anniversary of the 2025 meeting, specific deadlines have been set for stockholder proposals …
Artiva Biotherapeutics announced new employee inducement grants covering 288,800 restricted stock units for 17 new employees, effective July 14, 2026. These grants, made under Nasdaq listing Rule 5635(c)(4) and Artiva’s 2025 Inducement Plan, will vest over four years. The company is a clinical-stage biotechnology …
Search by ticker symbol or company name and select a result to open its chart.